Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Clinical trial NCT04139902 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04139902
Sponsor: Diwakar Davar
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Stage III Melanoma Stage IV

Start date: 2020-06-12
Primary completion: 2025-09-29
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.